NCT05357794View on ClinicalTrials.gov

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions
Mycosis Fungoides
Interventions
DRUG

Brentuximab vedotin

Given by Vein (IV)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05357794 - Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | Biotech Hunter | Biotech Hunter